login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
NOVARTIS AG-SPONSORED ADR (NVS) Stock News
USA
- NYSE:NVS -
US66987V1098
-
ADR
131.43
USD
+0.66 (+0.5%)
Last: 10/17/2025, 8:04:00 PM
131.43
USD
0 (0%)
After Hours:
10/17/2025, 8:04:00 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
NVS Latest News, Press Relases and Analysis
All
Press Releases
3 days ago - By: Chartmill
Novartis AG-Sponsored ADR (NYSE:NVS) Presents a Compelling Case for Value Investors
20 days ago - By: Chartmill
Novartis AG-Sponsored ADR (NYSE:NVS): A Strong Dividend Stock with High Profitability and Sound Financial Health
2 days ago - By: Benzinga
Novartis Cancer Drug Shows Sustained Benefit In Five-Year Breast Cancer Trial
2 days ago - By: Investor's Business Daily
- Mentions:
LLY
PFE
Eli Lilly Makes A Bold Claim For Its Biggest Cancer Drug
3 days ago - By: Benzinga
- Mentions:
AMGN
BIIB
TGTX
CLYM
Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity
6 days ago - By: Zacks Investment Research
- Mentions:
BMY
GILD
Will the Orbital Acquisition Strengthen BMY's Cell Therapy Portfolio?
6 days ago - By: The Motley Fool
- Mentions:
PPH
PFE
MRK
JNJ
...
Drug Stocks Just Had Their Best Week in 2 Decades. Should You Invest?
9 days ago - By: Zacks Investment Research
- Mentions:
BIIB
SUPN
PTCT
Can Biogen Stock Rebound as New Drugs Aim to Offset MS Sales Declines?
12 days ago - By: The Motley Fool
- Mentions:
BCE
JPM
CSCO
BAC
...
Cullen Capital Dumps 40% of BCE Holdings
17 days ago - By: Zacks Investment Research
Novartis AG (NVS) Hit a 52 Week High, Can the Run Continue?
18 days ago - By: Zacks Investment Research
- Mentions:
ALNY
PFE
BBIO
Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?
18 days ago - By: Bloomberg
- Mentions:
PFE
AstraZeneca, Sanofi Surge on Optimism Pharma Can Clinch US Price Deals
18 days ago - By: Bloomberg
Novartis Gains US Approval for New Approach to Chronic Hives
19 days ago - By: Bloomberg
A Top UK Midcap Performer’s US Plans Help it Evade Tariff Glare
Please enable JavaScript to continue using this application.